Daniel S. Char

 
ZUG, Switzerland—Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company focused on improving eyecare, has announced the appointment of Daniel S. Char to the role of chief legal officer, leading Oculis’ legal, compliance and corporate governance functions. Char brings more than 35 years of experience in global legal leadership experience at both large and smaller biotech companies to the new position at Oculis, according to the announcement. “We are delighted to welcome Daniel to Oculis,” said Riad Sherif, MD, chief executive officer of Oculis.





"This appointment exemplifies our continued execution of Oculis’ strategic plan to advance our innovative pipeline and bring differentiated products to patients starting with OCS-01 as the first topical eye drop in retina,” Dr. Sherif said.

Char has extensive legal expertise in corporate governance, compliance, drug development and commercialization, financing, licensing, and merger and acquisition transactions. He joins Oculis from ImmunoGen where he served as chief legal officer and corporate secretary. From 2018 to 2022, Char was the general counsel and corporate secretary of Evelo Biosciences. Before that, he held legal positions of increasing seniority with several biotech and medical device companies, including Smith & Nephew, Targanta Therapeutics and Biogen.

Char began his career as a corporate associate with Goodwin Procter. He holds a Juris doctor degree from Harvard Law School and a bachelor of arts in economics from Tufts University.

“I am thrilled to have the opportunity to join Oculis, a company with both an exceptional track record of strategic execution and multiple anticipated near-term milestones. I look forward to working alongside a talented team and supporting the company at this pivotal stage as it continues its journey to become a world leader in ophthalmology,” Char said.